{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T15:46:46Z","timestamp":1791820006137,"version":"4.3.4"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,4]],"date-time":"2026-06-04T00:00:00Z","timestamp":1780531200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["CM25\/00065"],"award-info":[{"award-number":["CM25\/00065"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004587","name":"Instituto de Salud Carlos III","doi-asserted-by":"publisher","award":["PI24\/01776"],"award-info":[{"award-number":["PI24\/01776"]}],"id":[{"id":"10.13039\/501100004587","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ijidonline.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Infectious Diseases"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.ijid.2026.108865","type":"journal-article","created":{"date-parts":[[2026,6,10]],"date-time":"2026-06-10T07:32:55Z","timestamp":1781076775000},"page":"108865","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Real-world experience with cefiderocol in hematologic patients with malignancies"],"prefix":"10.1016","volume":"171","author":[{"given":"Ana","family":"Martinez-Urrea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Mezzogori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antonio","family":"Gallardo-Pizarro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Balletto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Monz\u00f3-Gallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tommaso Francesco","family":"Aiello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniele Roberto","family":"Giacobbe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Teijon-Lumbreras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta","family":"Bodro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel","family":"Verdejo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Morata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Rivero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Pitart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Mensa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Garc\u00eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Bassetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alex","family":"Soriano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malgorzata","family":"Mikulska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8915-0683","authenticated-orcid":false,"given":"Carolina","family":"Garcia-Vidal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.ijid.2026.108865_bib0001","doi-asserted-by":"crossref","first-page":"2017","DOI":"10.1093\/jac\/dkac135","article-title":"Resistance to empirical \u03b2-lactams recommended in febrile neutropenia guidelines in gram-negative bacilli bloodstream infections in Spain: a multicentre study","volume":"77","author":"Chumbita","year":"2022","journal-title":"J Antimicrob Chemother"},{"issue":"4","key":"10.1016\/j.ijid.2026.108865_bib0002","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1097\/QCO.0000000000000745","article-title":"Multidrug-resistant, gram-negative infections in high-risk haematologic patients: an update on epidemiology, diagnosis and treatment","volume":"34","author":"Vidal","year":"2021","journal-title":"Curr Opin Infect Dis"},{"issue":"4","key":"10.1016\/j.ijid.2026.108865_bib0003","doi-asserted-by":"crossref","first-page":"733","DOI":"10.3390\/microorganisms10040733","article-title":"Effect of combination antibiotic empirical therapy on mortality in neutropenic cancer patients with Pseudomonas aeruginosa pneumonia","volume":"10","author":"Puig","year":"2022","journal-title":"Microorganisms"},{"issue":"6","key":"10.1016\/j.ijid.2026.108865_bib0004","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1093\/jac\/dkaf120","article-title":"Ceftazidime\/avibactam for the treatment of bloodstream infection due to carbapenemase-producing enterobacterales in onco-haematologic neutropenic patients (the TARZAN study)","volume":"80","author":"Escol\u00e0","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2026.108865_bib0005","unstructured":"10th \u2018European Conference on Infections in Leukaemia\u2019. https:\/\/www.ecil-leukaemia.com\/en\/resources\/resources-ecil [Accessed 30 May 2026]."},{"key":"10.1016\/j.ijid.2026.108865_bib0006","doi-asserted-by":"crossref","unstructured":"Bergas A, Puig AA, Cruz AF, Machado M, Novo A, Duin DV, et al. Real-life use of Ceftolozane\/Tazobactam for the treatment of bloodstream infection due to Pseudomonas aeruginosa in neutropenic hematologic patients: a matched control study (ZENITH Study). Carroll KC, editor. Microbiol Spectr 2022;10(3):e0229221. doi:10.1128\/spectrum.02292-21","DOI":"10.1128\/spectrum.02292-21"},{"issue":"4","key":"10.1016\/j.ijid.2026.108865_bib0007","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.cmi.2021.11.025","article-title":"European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant gram-negative bacilli (endorsed by European society of intensive care medicine)","volume":"28","author":"Paul","year":"2022","journal-title":"Clin Microbiol Infect"},{"issue":"2","key":"10.1016\/j.ijid.2026.108865_bib0008","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/S1473-3099(20)30796-9","article-title":"Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial","volume":"21","author":"Bassetti","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.ijid.2026.108865_bib0009","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/S1473-3099(20)30731-3","article-title":"Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial","volume":"21","author":"Wunderink","year":"2021","journal-title":"Lancet Infect Dis"},{"issue":"9","key":"10.1016\/j.ijid.2026.108865_bib0010","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1007\/s40121-024-01016-y","article-title":"Use of cefiderocol in adult patients: descriptive analysis from a prospective, multicenter, cohort study","volume":"13","author":"Giacobbe","year":"2024","journal-title":"Infect Dis Ther"},{"key":"10.1016\/j.ijid.2026.108865_bib0011","article-title":"Effectiveness and safety of cefiderocol treatment in patients with gram-negative bacterial infections in Spain in the early access programme: results of the PERSEUS study","author":"Cisneros","year":"2025","journal-title":"Eur J Clin Microbiol Infect Dis"},{"issue":"12","key":"10.1016\/j.ijid.2026.108865_bib0012","doi-asserted-by":"crossref","first-page":"14132","DOI":"10.3390\/cimb46120846","article-title":"Updates on the activity, efficacy and emerging mechanisms of resistance to cefiderocol","volume":"46","author":"Bianco","year":"2024","journal-title":"Curr Issues Mol Biol"},{"issue":"S1","key":"10.1016\/j.ijid.2026.108865_bib0013","doi-asserted-by":"crossref","DOI":"10.1111\/tid.14169","article-title":"Global impact of antibacterial resistance in patients with hematologic malignancies and hematopoietic cell transplant recipients","volume":"25","author":"Gottesdiener","year":"2023","journal-title":"Transpl Infect Dis"},{"issue":"1","key":"10.1016\/j.ijid.2026.108865_bib0014","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2024.106376","article-title":"Real-world multicentre study of cefiderocol treatment of immunocompromised patients with infections caused by multidrug-resistant gram-negative bacteria: CEFI-ID","volume":"90","author":"Soueges","year":"2025","journal-title":"J Infect"},{"issue":"1","key":"10.1016\/j.ijid.2026.108865_bib0015","doi-asserted-by":"crossref","first-page":"88","DOI":"10.3390\/medicina60010088","article-title":"Stenotrophomonas maltophilia infections in haematological malignancies and hematopoietic stem cell transplantation: a case series including cefiderocol-based regimens","volume":"60","author":"Lupia","year":"2024","journal-title":"Medicina (Mex)"},{"issue":"6","key":"10.1016\/j.ijid.2026.108865_bib0016","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1007\/s00277-021-04737-z","article-title":"Successful cefiderocol therapy of severe infections due to difficult-to-treat Pseudomonas aeruginosa in two allogeneic hematopoietic stem cell transplantation recipients","volume":"101","author":"Gras","year":"2022","journal-title":"Ann Hematol"},{"issue":"6","key":"10.1016\/j.ijid.2026.108865_bib0017","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1093\/jac\/dkab015","article-title":"Cefiderocol: a novel siderophore cephalosporin for multidrug-resistant gram-negative bacterial infections","volume":"76","author":"Parsels","year":"2021","journal-title":"J Antimicrob Chemother"},{"issue":"8","key":"10.1016\/j.ijid.2026.108865_bib0018","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1007\/s40121-023-00854-6","article-title":"Cefiderocol versus Colistin for the treatment of carbapenem-resistant Acinetobacter baumannii complex bloodstream infections: a retrospective, propensity-score adjusted, monocentric cohort study","volume":"12","author":"Bavaro","year":"2023","journal-title":"Infect Dis Ther"},{"issue":"4","key":"10.1016\/j.ijid.2026.108865_bib0019","doi-asserted-by":"crossref","DOI":"10.1093\/jacamr\/dlad085","article-title":"Cefiderocol-containing regimens for the treatment of carbapenem-resistant A. baumannii ventilator-associated pneumonia: a propensity-weighted cohort study","volume":"5","author":"Rando","year":"2023","journal-title":"JAC-Antimicrob Resist"},{"key":"10.1016\/j.ijid.2026.108865_bib0020","article-title":"Resistance profiles of carbapenemase-producing enterobacterales in a large centre in England: are we already losing cefiderocol?","author":"Baltas","year":"2024","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijid.2026.108865_bib0021","article-title":"Rectal colonisation by multidrug-resistant gram-negative bacteria and subsequent bacteraemia in haematological patients","author":"Pizarro","year":"2025","journal-title":"Clin Microbiol Infect"},{"issue":"4","key":"10.1016\/j.ijid.2026.108865_bib0022","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.ijantimicag.2016.01.011","article-title":"Carbapenemase-producing Klebsiella pneumoniae bloodstream infections in neutropenic patients with haematological malignancies or aplastic anaemia: analysis of 50 cases","volume":"47","author":"Tofas","year":"2016","journal-title":"Int J Antimicrob Agents"},{"issue":"1","key":"10.1016\/j.ijid.2026.108865_bib0023","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12941-023-00586-y","article-title":"Bloodstream infections due to carbapenem-resistant Enterobacteriaceae in hematological patients: assessment of risk factors for mortality and treatment options","volume":"22","author":"Zhang","year":"2023","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"7","key":"10.1016\/j.ijid.2026.108865_bib0024","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.jiac.2024.01.007","article-title":"Ceftazidime-avibactam in the treatment of bacteremia due to carbapenem-resistant gram-negative bacteria in hematological patients: experience in a single center","volume":"30","author":"Zhen","year":"2024","journal-title":"J Infect Chemother"},{"key":"10.1016\/j.ijid.2026.108865_bib0025","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ijid.2017.03.021","article-title":"Clinical efficacy of ceftazidime\/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients","volume":"59","author":"Cast\u00f3n","year":"2017","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.ijid.2026.108865_bib0026","doi-asserted-by":"crossref","unstructured":"El Ghali A, Coyne AJK, Lucas K, Tieman M, Xhemali X, Lau SP, et al. Cefiderocol: early clinical experience for multi-drug resistant gram-negative infections. Babiker A, editor. Microbiol Spectr 2024;12(2):e03108-23. doi:10.1128\/spectrum.03108-23","DOI":"10.1128\/spectrum.03108-23"},{"issue":"3","key":"10.1016\/j.ijid.2026.108865_bib0027","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/j.cmi.2022.11.005","article-title":"Real-world clinical outcome of cefiderocol for treatment of multidrug-resistant non-fermenting, gram negative bacilli infections: a case series","volume":"29","author":"Hoellinger","year":"2023","journal-title":"Clin Microbiol Infect"},{"issue":"6","key":"10.1016\/j.ijid.2026.108865_bib0028","doi-asserted-by":"crossref","first-page":"723","DOI":"10.3390\/antibiotics11060723","article-title":"Cefiderocol: systematic review of mechanisms of resistance, heteroresistance and In vivo emergence of resistance","volume":"11","author":"Karakonstantis","year":"2022","journal-title":"Antibiotics"}],"container-title":["International Journal of Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S120197122600500X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S120197122600500X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T14:51:27Z","timestamp":1791816687000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S120197122600500X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":28,"alternative-id":["S120197122600500X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108865","relation":{},"ISSN":["1201-9712"],"issn-type":[{"value":"1201-9712","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Real-world experience with cefiderocol in hematologic patients with malignancies","name":"articletitle","label":"Article Title"},{"value":"International Journal of Infectious Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijid.2026.108865","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd on behalf of International Society for Infectious Diseases.","name":"copyright","label":"Copyright"}],"article-number":"108865"}}